In vivo CAR T: Faster, cheaper, and more effective cancer care
Dec 16, 2024 · Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
First patient enrolled in fostamatinib trial for sickle cell disease
5 days ago · Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle cell disease.
Coherus announces positive Phase II results for cancer treatment
3 days ago · Coherus BioSciences announced the final data from its Phase II clinical trial. The trial evaluated casdozokitug (casdozo), a selective Interleukin-27-targeting antibody. It was tested in combination with atezolizumab and bevacizumab for treating unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC). The results were presented at the 2025 ASCO Gastrointestinal Cancers ...
FDA greenlights AI-developed drug targeting solid tumors
Dec 4, 2024 · Insilico Medicine's AI-designed drug ISM5939, targeting ENPP1, receives FDA IND clearance for solid tumour treatment.
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. The current shift focuses on enhancing their efficacy by addressing the crucial need for robust T cell responses, an apparent bottleneck for broader impact ...
New AI model may enable more targeted prostate cancer treatment
Oct 30, 2024 · Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
Drug Target Review: Leading Research & Insights in Drug Discovery
Featured The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing Explore how a Weight of Evidence (WoE) approach uses in vitro methods and artificial intelligence (AI) to transform carcinogenicity risk assessment, reducing reliance on animal studies while enhancing compliance with FDA and ICH guidelines.
How AI will reshape pharma in 2025 - drugtargetreview.com
Dec 20, 2024 · Discover the impact of AI on pharmaceutical drug development. Find out how AI and machine learning are reshaping the industry and its future.
Genetic mechanism could lead to RNA therapies for mental health
Jan 9, 2025 · Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
LB Pharmaceuticals announces positive schizophrenia trial data
Jan 15, 2025 · LB Pharmaceuticals, a clinical-stage biopharmaceutical company focused on psychiatric disease therapies, announced positive results from its Phase II NOVA 1 trial of LB-102. The trial evaluated LB-102, a once-daily, orally administered small molecule, as a potential first-in-class benzamide antipsychotic for acute schizophrenia.